Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom medical research council AML11 trial. Blood. 2001;98(5):1312–1320. doi:10.1182/blood.v98.5.1312
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• Pan R, Ruvolo V, Mu H, et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017;32(6):748–760. doi:10.1016/j.ccell.2017.11.003
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341. doi:10.1016/j.stem.2012.12.013
   PubMed Web of Science ®Google Scholar
• Campos EDV, Pinto R. Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia. Hematol Transfus Cell Ther. 2019;41(2):169–177. doi:10.1016/j.htct.2018.09.001
   PubMedGoogle Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407. doi:10.1002/ajh.25000
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):145–153. doi:10.1016/j.beha.2019.05.008
   PubMed Web of Science ®Google Scholar
• Das M. Venetoclax with decitabine or azacitidine for AML. Lancet Oncol. 2018;19(12):e672. doi:10.1016/S1470-2045(18)30824-6
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765–1773. doi:10.1182/blood-2012-04-423160
   PubMed Web of Science ®Google Scholar
• Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122(17):3034–3044. doi:10.1182/blood-2013-04-495374
   PubMed Web of Science ®Google Scholar
• Gravina GL, Mancini A, Sanita P, et al. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2015;15(1):941. doi:10.1186/s12885-015-1936-z
   PubMedGoogle Scholar
• Haines JD, Herbin O, de la Hera B, et al. Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. Nat Neurosci. 2015;18(4):511–520. doi:10.1038/nn.3953
   PubMed Web of Science ®Google Scholar
• Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human Phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142–4150. doi:10.1200/JCO.2015.65.3949
   PubMed Web of Science ®Google Scholar
• Etchin J, Montero J, Berezovskaya A, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016;30(1):190–199. doi:10.1038/leu.2015.194
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621–4634. doi:10.1182/blood-2012-05-429506
   PubMed Web of Science ®Google Scholar
• Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155–165. doi:10.1038/leu.2013.115
   PubMed Web of Science ®Google Scholar
• Fischer MA, Friedlander SY, Arrate MP, et al. Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. Blood Adv. 2020;4(3):586–598. doi:10.1182/bloodadvances.2019000359
   PubMed Web of Science ®Google Scholar
• Wang AY, Fang MM, Jiang H, et al. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia. Biomed Pharmacother. 2022;153:113527. doi:10.1016/j.biopha.2022.113527
   PubMed Web of Science ®Google Scholar
• Bogenberger J, Whatcott C, Hansen N, et al. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017;8(63):107206–107222. doi:10.18632/oncotarget.22284
   PubMedGoogle Scholar
• Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49. doi:10.1186/s13045-021-01062-w
   PubMed Web of Science ®Google Scholar
• Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2020;106(3):894–898. doi:10.3324/haematol.2020.252569
   Web of Science ®Google Scholar
• Niu X, Zhao J, Ma J, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22(17):4440–4451. doi:10.1158/1078-0432.CCR-15-3057
   PubMed Web of Science ®Google Scholar
• Luedtke DA, Su Y, Liu S, et al. Inhibition of XPO1 enhances cell death induced by ABT- 199 in acute myeloid leukaemia via Mcl-1. J Cell Mol Med. 2018;22(12):6099–6111. doi:10.1111/jcmm.13886
   PubMed Web of Science ®Google Scholar
• Schwartz L, Seyfried T, Alfarouk KO, Da Veiga Moreira J, Fais S. Out of Warburg effect: an effective cancer treatment targeting the tumor specific metabolism and dysregulated pH. Semin Cancer Biol. 2017;43:134–138. doi:10.1016/j.semcancer.2017.01.005
   PubMed Web of Science ®Google Scholar
• Chae HD, Mitton B, Lacayo NJ, Sakamoto KM. Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA. Leukemia. 2015;29(6):1379–1389. doi:10.1038/leu.2014.350
   PubMed Web of Science ®Google Scholar
• Li WJ, Wu DW, Zhou YF, et al. Prognostic biomarker replication factor C subunit 5 and its correlation with immune infiltrates in acute myeloid leukemia. Hematology. 2022;27(1):555–564. doi:10.1080/16078454.2022.2072064
   PubMed Web of Science ®Google Scholar
• Li H, Bi K, Feng S, et al. CircRNA circ_POLA2 is Upregulated in Acute Myeloid Leukemia (AML) and Promotes Cell Proliferation by Suppressing the Production of Mature miR-34a. Cancer Manag Res. 2021;13:3629–3637. doi:10.2147/CMAR.S281690
   PubMed Web of Science ®Google Scholar
• Hartmann E, Fernandez V, Moreno V, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol. 2008;26(30):4966–4972. doi:10.1200/JCO.2007.12.0410
   PubMed Web of Science ®Google Scholar
• Elgaaen BV, Haug KB, Wang J, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One. 2010;5:e13837. doi:10.1371/journal.pone.0013837
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Yu J, et al. Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro. Oncol Rep. 2018;40(5):2477–2486. doi:10.3892/or.2018.6659
   PubMed Web of Science ®Google Scholar
• Xu Q, Hu C, Zhu Y, et al. ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics. Cancer Lett. 2020;482:126–135. doi:10.1016/j.canlet.2020.01.011
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen X, Zhang L, et al. POLE2 facilitates the malignant phenotypes of glioblastoma through promoting AURKA-mediated stabilization of FOXM1. Cell Death Dis. 2022;13(1):61. doi:10.1038/s41419-021-04498-7
   PubMed Web of Science ®Google Scholar
• Fan Z, Bai Y, Zhang Q, et al. CircRNA circ_POLA2 promotes lung cancer cell stemness via regulating the miR-326/GNB1 axis. Environ Toxicol. 2020;35(10):1146–1156. doi:10.1002/tox.22980
   PubMed Web of Science ®Google Scholar
• Wu HY, Li KX, Pan WY, et al. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway. Int Immunopharmacol. 2022;104:108497. doi:10.1016/j.intimp.2021.108497
   PubMed Web of Science ®Google Scholar
• Fisher JG, Walker CJ, Doyle AD, et al. Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. Front Oncol. 2021;11:785635. doi:10.3389/fonc.2021.785635
   PubMed Web of Science ®Google Scholar
• Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021;5(4):994–1002. doi:10.1182/bloodadvances.2020003902
   PubMed Web of Science ®Google Scholar
• Pratz KW, Chai X, Xie J, et al. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: from a US Third Party Payer Perspective. Pharmacoeconomics. 2022;40(8):777–790. doi:10.1007/s40273-022-01145-7
   PubMed Web of Science ®Google Scholar
• Kennedy VE, Hui G, Azenkot T, et al. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022;97(6):E191–E194. doi:10.1002/ajh.26524
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Winters A, McMahon C, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022;57(2):160–166. doi:10.1038/s41409-021-01476-7
   PubMed Web of Science ®Google Scholar
• Winters AC, Bosma G, Abbott D, et al. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022;28(10):694.e1–694.e9. doi:10.1016/j.jtct.2022.07.022
   PubMedGoogle Scholar